Sponsors Work with FDA to Streamline Combo Product Development and Oversight

A growing volume of combination products, particularly for cutting-edge gene and cellular therapies and other new medical technologies, is creating challenges for FDA s Office of Combination Products (OCP) and its role in advising on whether a new combination therapy should be designated as a drOriginal Article